|
Tweet | ||
233 * | Mon, 8/10/2015, 2:00 PM - 3:50 PM | CC-201 | |
Recent Developments in Analyzing Survival Endpoint Adjusting for Treatment Switching/Alternative Therapy in Late-Phase Oncology Trials — Topic Contributed Papers | |||
International Chinese Statistical Association , Biometrics Section | |||
Organizer(s): Eileen Liao, Takeda Pharmaceuticals | |||
Chair(s): Huyuan Yang, Takeda Pharmaceuticals | |||
2:05 PM | MSM Versus IPCW in Survival Analysis for Adjusting Confounding Due to Taking Alternative Therapy in Phase III Oncology Clinical Trials — Jing Xu, Takeda Pharmaceuticals | ||
2:25 PM | Comparing Several Recensoring Methods of RPSFT Model for the Analysis of OS Data Adjusted for Treatment Switching in Phase III Clinical Trials — Jason Yuan, Agios Pharmaceuticals ; Connie Lee, Takeda Pharmaceuticals | ||
2:45 PM | Sensitivity Analyses Adjusting Treatment Crossover for Survival Estimate: A Case Study — Kathy Zhang, Medivation, Inc. ; Ying Tian, Biogen ; Alan Rong, Astellas ; Hua Yu, Biomarin ; Xuesong Guan, Amgen | ||
3:05 PM | Using Knowledge of the Data Structure in Applications of the Parametric G-Formula — Jessica Young, Harvard School of Public Health | ||
3:25 PM | Discussant: Lijun Zhang, DB V/OTS/CDER/FDA | ||
3:45 PM | Floor Discussion |
For program information, contact the JSM Registration Department or phone (888) 231-3473.
For Professional Development information, contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
2015 JSM Online Program Home
ASA Meetings Department
732 North Washington Street, Alexandria, VA 22314
(703) 684-1221 • meetings@amstat.org
Copyright © American Statistical Association.